Choose from ready-to-use products or get customized solutions for your technology or workflow.
We offer end-to-end development and optimization of allele-specific assays using our proprietary Switch-Blocker™ chemistry, tailored to your genomic targets and sample types.
Our collaborative development process ensures alignment, transparency, and technical success at each phase. We work closely with your team from design through delivery, maintaining high scientific standards and open communication.
Aegea provides a range of products and services, including research-use-only (RUO) kits, and custom assay development. These offerings are designed to integrate seamlessly into existing laboratory workflows, enhancing the sensitivity and specificity of molecular analyses.
Aegea’s solutions are tailored for a diverse clientele, including pharmaceutical and biotech companies, life science researchers, and clinical laboratories developing new technologies and assays for DNA mutation detection. Organizations seeking to improve the detection of rare genetic events or to develop multiplexed assays will find Aegea’s technologies particularly advantageous.
Yes. Aegea collaborates with clients to develop custom assays and adapt its technologies to various platforms. This collaborative approach ensures that the assays meet specific research or clinical needs.
To explore collaboration opportunities, you can contact us here LINK. We welcome partnerships that aim to advance molecular diagnostics and personalized medicine.
Best-in-class Switch-Blocker technology is unmatched in analytic sensitivity for rare DNA mutation detection. The company owns a suite of nucleic acid amplification technologies and a robust portfolio of 11 issued U.S. patents, and a proven track record in clinical research and validation.